- Home
- INBK vs YMAB Comparison
INBK vs YMAB Comparison
Compare INBK & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBK
- YMAB
- Stock Information
- Founded
- INBK 1999
- YMAB 2015
- Country
- INBK United States
- YMAB United States
- Employees
- INBK N/A
- YMAB N/A
- Industry
- INBK Major Banks
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- INBK Finance
- YMAB Health Care
- Exchange
- INBK Nasdaq
- YMAB Nasdaq
- Market Cap
- INBK 228.1M
- YMAB 270.5M
- IPO Year
- INBK N/A
- YMAB 2018
- Fundamental
- Price
- INBK $27.21
- YMAB $4.80
- Analyst Decision
- INBK Buy
- YMAB Buy
- Analyst Count
- INBK 4
- YMAB 11
- Target Price
- INBK $40.50
- YMAB $18.73
- AVG Volume (30 Days)
- INBK 32.8K
- YMAB 300.8K
- Earning Date
- INBK 04-23-2025
- YMAB 03-04-2025
- Dividend Yield
- INBK 0.90%
- YMAB N/A
- EPS Growth
- INBK 203.16
- YMAB N/A
- EPS
- INBK 2.88
- YMAB N/A
- Revenue
- INBK $117,652,000.00
- YMAB $87,685,000.00
- Revenue This Year
- INBK $3.03
- YMAB $20.07
- Revenue Next Year
- INBK $16.38
- YMAB $8.76
- P/E Ratio
- INBK $9.29
- YMAB N/A
- Revenue Growth
- INBK 39.44
- YMAB 3.38
- 52 Week Low
- INBK $24.18
- YMAB $4.25
- 52 Week High
- INBK $43.26
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- INBK 42.81
- YMAB 44.09
- Support Level
- INBK $25.54
- YMAB $4.25
- Resistance Level
- INBK $27.12
- YMAB $5.25
- Average True Range (ATR)
- INBK 0.97
- YMAB 0.31
- MACD
- INBK 0.17
- YMAB 0.03
- Stochastic Oscillator
- INBK 37.44
- YMAB 51.40
About INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking/treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.